FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia

Background The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. Methods Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, prospective and randomized study of 626 patients with non-dialysis-dependent CKD, anaemia and iron deficiency not receiving erythropoiesis-stimulating agents (ESAs). Patients were randomized (1:1:2) to intravenous (IV) ferric carboxymaltose (FCM), targeting a higher (400–600 µg/L) or lower (100–200 µg/L) ferritin or oral iron therapy. The primary end point was time to initiation of other anaemia management (ESA, other iron therapy or blood transfusion) or haemoglobin (Hb) trigger of two consecutive values <10 g/dL during Weeks 8–52. Results The primary end point occurred in 36 patients (23.5%), 49 patients (32.2%) and 98 patients (31.8%) in the high-ferritin FCM, low-ferritin FCM and oral iron groups, respectively [hazard ratio (HR): 0.65; 95% confidence interval (CI): 0.44–0.95; P = 0.026 for high-ferritin FCM versus oral iron]. The increase in Hb was greater with high-ferritin FCM versus oral iron (P = 0.014) and a greater proportion of patients achieved an Hb increase ≥1 g/dL with high-ferritin FCM versus oral iron (HR: 2.04; 95% CI: 1.52–2.72; P < 0.001). Rates of adverse events and serious adverse events were similar in all groups. Conclusions Compared with oral iron, IV FCM targeting a ferritin of 400–600 µg/L quickly reached and maintained Hb level, and delayed and/or reduced the need for other anaemia management including ESAs. Within the limitations of this trial, no renal toxicity was observed, with no difference in cardiovascular or infectious events. ClinicalTrials.gov number NCT00994318.

[1]  E. Daugas,et al.  Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  F. Locatelli,et al.  Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  I. Macdougall,et al.  The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  N. Vaziri Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  D. Gilbertson,et al.  Red blood cell transfusion use in patients with chronic kidney disease. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  R. Testa,et al.  Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  M. Brookhart,et al.  Changing patterns of anemia management in US hemodialysis patients. , 2012, The American journal of medicine.

[8]  A. Webster,et al.  Parenteral versus oral iron therapy for adults and children with chronic kidney disease. , 2012, The Cochrane database of systematic reviews.

[9]  A. Mangione,et al.  A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  H. Uno,et al.  Erythropoietic response and outcomes in kidney disease and type 2 diabetes. , 2010, The New England journal of medicine.

[11]  David W. Johnson,et al.  Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease , 2010, Annals of Internal Medicine.

[12]  A. Gafter-Gvili,et al.  Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  R. Califf,et al.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. , 2008, Kidney international.

[14]  A. Kausz,et al.  Ferumoxytol for treating iron deficiency anemia in CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[15]  C. Stehman-Breen,et al.  Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[16]  Shixiang Wang,et al.  Intravenous Iron Sucrose in Chinese Hemodialysis Patients with Renal Anemia , 2008, Blood Purification.

[17]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[18]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[19]  D. V. Van Wyck,et al.  A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. , 2005, Kidney international.

[20]  S. Fishbane,et al.  Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. , 2005, Kidney international.

[21]  G. Bailie,et al.  Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on Dialysis , 2005, Nephron Clinical Practice.

[22]  A. Kausz,et al.  Iron therapy in the pediatric hemodialysis population , 2004, Pediatric Nephrology.

[23]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[24]  J. Kvasnička,et al.  [Iron supplementation during erythropoietin therapy in patients on hemodialysis]. , 1996, Vnitrni lekarstvi.

[25]  I. Macdougall,et al.  A randomized controlled study of iron supplementation in patients treated with erythropoietin. , 1996, Kidney international.

[26]  R. Garrick A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .

[27]  L. Leibovici,et al.  Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[29]  Giacomo Mengozzi,et al.  Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. , 1991, Nephron.